CGT Development Is Booming, but Manufacturing Workforce Must Keep Up

Gene, Cell, + RNA Therapy Landscape Q3 2023 Report

Q3 2023 saw 3,866 therapies in development; 53% of those were gene therapies, 25% RNA therapies, and 22% non-genetically modified cell therapies.

Cell and Gene Therapy Global Regulatory Report

The first Cell and Gene Therapy Regulatory Report from Citeline and ISCT provides a global overview of the cell and gene therapy landscape.

The State of Innovation in Europe

Europe’s drug innovative pipeline has reached a plateau, and is underexposed to high-growth areas such as oncology, cell and gene therapy.